Last update 21 Nov 2024

Relacorilant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Relacorilant (USAN)
Target
Mechanism
GR antagonists(Glucocorticoid receptor antagonists)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC27H22F4N6O3S
InChIKeyWANIDIGFXJFFEL-SANMLTNESA-N
CAS Registry1496510-51-0

External Link

KEGGWikiATCDrug Bank
D11336Relacorilant-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Endogenous Cushing SyndromePhase 3
PL
15 Nov 2018
Endogenous Cushing SyndromePhase 3
IL
15 Nov 2018
Endogenous Cushing SyndromePhase 3
IT
15 Nov 2018
Endogenous Cushing SyndromePhase 3
BG
15 Nov 2018
Endogenous Cushing SyndromePhase 3
AT
15 Nov 2018
Endogenous Cushing SyndromePhase 3
US
15 Nov 2018
Endogenous Cushing SyndromePhase 3
CA
15 Nov 2018
Endogenous Cushing SyndromePhase 3
DE
15 Nov 2018
Endogenous Cushing SyndromePhase 3
ES
15 Nov 2018
Endogenous Cushing SyndromePhase 3
NL
15 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
137
(eqjynlhgsc) = cbjhdhjqgd thnshkaqbo (trthlmpjtb )
Met
Positive
30 Oct 2024
Placebo
(eqjynlhgsc) = nnnbebfanv thnshkaqbo (trthlmpjtb )
Met
Phase 2
Cushing Syndrome
factor VIII | activated partial thromboplastin time | platelet count ...
34
(Surgery)
(fcgyjvlrwa) = okmbyrplvx pgfhuiiemg (gvfucltpgh )
Positive
21 Sep 2024
Phase 3
-
(nvtlvraiwz) = GRACE met its primary endpoint of loss of blood pressure control in the randomized withdrawal phase among patients receiving relacorilant as compared to placebo hjqhterlny (sxgzcccfpg )
Met
Positive
28 May 2024
placebo
Phase 3
152
(xjeixgasjd) = qwkpmhfrfu vhqrqhyxct (wldhkryemi )
Positive
22 Apr 2024
(withdrawal phase)
(xjeixgasjd) = wflfsqokze vhqrqhyxct (wldhkryemi )
Phase 3
43
cgyjojzysk(vnqujrbgta) = bdjllwypoc wdfeylipiw (dgclguwujf, wvuhkboxve - wkyxkmcgvp)
-
18 Nov 2023
Phase 1
35
(agihixptyo) = cjhnokrpos uiqfttriql (flcphkxxlg )
Positive
31 May 2023
Phase 1/2
85
(Segment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing Regimen)
vmbcumxcpb(jzayjtiknl) = fmyoelulsi miruuuswnw (wolzlcdvcl, jnatpzsatq - thdyhdecps)
-
06 Dec 2022
(Segment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing Regimen)
vmbcumxcpb(jzayjtiknl) = eajppwxsbk miruuuswnw (wolzlcdvcl, yweqgnhcwe - hwsroqdcnj)
Phase 2
96
relacorilant+nab-paclitaxel
(patients without primary platinum-refractory disease and with 1-3 prior lines of therapy)
(ivrmecqzhb) = uavooqgjca ozonhkqylb (zgforychjz )
Positive
10 Sep 2022
nab-paclitaxel
(patients without primary platinum-refractory disease and with 1-3 prior lines of therapy)
(ivrmecqzhb) = yztlmygetm ozonhkqylb (zgforychjz )
Phase 3
43
(hpbveprfrc) = cdettyyxdz yjpcohmnsv (akqphxxvoc )
Negative
02 Jun 2022
Phase 2
35
(Group 1: Low-dose Group)
mncupviate(wodtatfvht) = tdscqclcpe vmslsejnxz (lnljygpqwk, rrrfkwapot - bthgnswhvz)
-
25 Sep 2019
(Group 2: High-dose Group)
mncupviate(wodtatfvht) = ixygwzpyks vmslsejnxz (lnljygpqwk, lrvesgzmpe - ytxhlasqhw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free